Juan José
Lasarte Sagastibelza
Catedrático de Universidad
Publicaciones en las que colabora con Juan José Lasarte Sagastibelza (29)
2024
-
Tethered IL15-IL15Rα augments antitumor activity of CD19 CAR-T cells but displays long-term toxicity in an immunocompetent lymphoma mouse model
Journal for immunotherapy of cancer, Vol. 12, Núm. 7
2023
-
FOXP3 expression diversifies the metabolic capacity and enhances the efficacy of CD8 T cells in adoptive immunotherapy of melanoma
Molecular Therapy, Vol. 31, Núm. 1, pp. 48-65
2022
-
Gemcitabine-mediated depletion of immunosuppressive dendritic cells enhances the efficacy of therapeutic vaccination
Frontiers in Immunology, Vol. 13
-
Identification of HLA class I-restricted immunogenic neoantigens in triple negative breast cancer
Frontiers in Immunology, Vol. 13
-
Impact of tumor microenvironment on adoptive T cell transfer activity
International Review of Cell and Molecular Biology (Elsevier Inc.), pp. 1-31
-
Overcoming T cell dysfunction in acidic pH to enhance adoptive T cell transfer immunotherapy
OncoImmunology, Vol. 11, Núm. 1
-
TCR-induced FOXP3 expression by CD8+ T cells impairs their anti-tumor activity
Cancer Letters, Vol. 528, pp. 45-58
-
Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells
Journal for ImmunoTherapy of Cancer, Vol. 10, Núm. 8
2021
-
Epitope spreading driven by the joint action of CART cells and pharmacological STING stimulation counteracts tumor escape via antigen-loss variants
Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 11
-
The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1+ tumour-infiltrating lymphocytes
British Journal of Cancer, Vol. 124, Núm. 6, pp. 1138-1149
2020
-
Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens
Journal for immunotherapy of cancer, Vol. 8, Núm. 1
2019
-
Genetic Modification of CD8+ T Cells to Express EGFR: Potential Application for Adoptive T Cell Therapies
Frontiers in Immunology, Vol. 10
-
PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas
Blood, Vol. 133, Núm. 22, pp. 2401-2412
-
Short-Term Local Expression of a PD-L1 Blocking Antibody from a Self-Replicating RNA Vector Induces Potent Antitumor Responses
Molecular Therapy, Vol. 27, Núm. 11, pp. 1892-1905
-
Therapeutic Effect of Irreversible Electroporation in Combination with Poly-ICLC Adjuvant in Preclinical Models of Hepatocellular Carcinoma
Journal of Vascular and Interventional Radiology, Vol. 30, Núm. 7, pp. 1098-1105
2018
-
Immunomodulatory properties of carvone inhalation and its effects on contextual fear memory in mice
Frontiers in Immunology, Vol. 9, Núm. JAN
-
The Toll like receptor 4 ligand cold-inducible RNA-binding protein as vaccination platform against cancer
OncoImmunology, Vol. 7, Núm. 4
2017
-
Blockage of FOXP3 transcription factor dimerization and FOXP3/AML1 interaction inhibits T regulatory cell activity: sequence optimization of a peptide inhibitor
Oncotarget, Vol. 8, Núm. 42, pp. 71709-71724
-
Expansion of tumor-infiltrating CD8+ T cells expressing PD-1 improves the efficacy of adoptive T-cell therapy
Cancer Research, Vol. 77, Núm. 13, pp. 3672-3684
-
IL-10 expression defines an immunosuppressive dendritic cell population induced by antitumor therapeutic vaccination
Oncotarget, Vol. 8, Núm. 2, pp. 2659-2671